Hoth ends HT-001 Phase 2a trial early on positive interim results
HOTH•Hoth Therapeutics is ending its HT-001 Phase 2a trial early after strong interim efficacy findings. It plans to present the data to the FDA for feedback on a potential Phase 3 program; a launch depends on regulatory feedback and completing required development work.
1. Trial and next steps
Hoth Therapeutics is ending its Phase 2a trial of HT-001 early following strong interim efficacy findings. The investigational topical treatment targets skin toxicity associated with EGFR inhibitor cancer therapies. Hoth plans to present the data to the FDA and seek feedback on a potential Phase 3 program, whose launch depends on regulatory feedback and completion of required development work.
